The U.S. Food and Drug Administration has approved a controversial Alzheimer’s disease treatment for broad use—with caveats.
have signed it. “Every day of delay in patient access to this therapy may result in treatable patients progressing,” the letter reads.
But although Snider is excited about the drug, she also stresses that it should be “only the beginning,” and she hopes other, better therapies will follow. Among other concerns, Snider worries about lecanemab’s potentially high cost. After the FDA approval, Eisai suggested it would have an annual cost of more than $25,000 for an average person, with additional costs for its infusions and monitoring.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA grants accelerated approval to Alzheimer's drug for people with early stage diseaseBREAKING: FDA grants accelerated approval to new Alzheimer's treatment that can slow cognitive decline in people with early stages of the disease.
Read more »
FDA grants fast-track approval to experimental Alzheimer's drugThe FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.
Read more »
The FDA Will Now Allow You To Buy Abortion Pills At Normal PharmaciesThe FDA has changed its rules to make it easier for patients to access abortion pills, which until now were difficult to get.
Read more »
The FDA Will Now Allow Abortion Pills to be Sold at Retail PharmaciesPreviously, the first in the two-pill cycle used in medication abortions—mifepristone—had to be accessed via specific doctors and/or mail-order pharmacies.
Read more »
Tirzepatide drug fast-tracked for weight loss indication by FDA: What to know about itAn injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.
Read more »